Successful Treatment of Fanconi Anemia and T-Cell Acute Lymphoblastic Leukemia

Clicks: 333
ID: 98408
2012
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Popular

Ranked #9 of 22 articles by views in case reports in hematology

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Fanconi anemia is associated with an increased risk of malignancy. Patients are sensitive to the toxic effects of chemotherapy. We report the case of a patient with Fanconi anemia who developed T-cell acute lymphoblastic leukemia. He experienced chemotherapy-related complications including prolonged neutropenia, grade IV vincristine neuropathy, and disseminated aspergillosis. He was successfully treated with modified dosing of cytarabine and intrathecal methotrexate followed by allogeneic bone marrow transplant. The aspergillosis was treated with systemic antifungal treatment and surgical resection. Now 30 months after bone marrow transplant the patient is without evidence of aspergillosis or leukemia.
Reference Key
flatt2012successfulcase Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Flatt, Terrie;Neville, Kathleen;Lewing, Karen;Dalal, Jignesh;
Journal case reports in hematology
Year 2012
DOI
DOI not found
URL
http://dx.doi.org/10.1155/2012/396395
Keywords
Biology (General) Diseases of the blood and blood-forming organs

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.